Probiodrug (Germany) a clinical-stage biopharmaceutical company focused enzyme inhibitors for Alzheimer’s and inflammatory disease, closed a $20M Series C financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Sciences Partners, Biogen Idec New Ventures, TVM Capital, HBM BioVentures, Goodvent and Wellington Management Company.

Delenex (Switzerland) a preclinical-stage biopharmaceutical company focused on CNS and dermatological diseases closed a $19.3M Series A financing, bringing the total round to $38.4M. Participants include Novo Ventures, SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners.

MTM Laboratories (Germany) a commercial-stage molecular diagnostics company focused on cervical cancer, closed on a $9M Series C financing bringing the total round to $65M. Participants include Gilde Healthcare Partners, LBBW Venture Capital, HBM BioVentures and HBM BioCapital.

Cylene Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on multiple myeloma, closed a $12M Series D financing. Participants include Sanderling Ventures, HBM BioVentures, Novartis Venture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments.

Cylene Pharmaceuticals (Sa Diego, CA) a clinical-stage small molecule company focused on broad spectrum anti-proliferative activity against diverse cancer set of cancers, closed a $12M Series D financing. Participants include Sanderling Ventures, HBM BioVentures, Novartis Venture Fund, BioVentures Investors, Lilly Ventures and Morningside Venture Investments.

Nereus Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on non-small cell lung cancer and myeloma, closed a $20M Series E financing. Participants include HBM BioVentures, Alta Partners, Forward Ventures, Gimv, Advent International, Pacific Venture Group, Roche Venture Fund and Astellas Venture Management.

PTC Therapeutics (South Plainfield, NJ) a clinical-stage small molecule company focused on CF, hemophilia and muscular dystrophy, closed a $50M Series E financing. Participants include The Column Group, Delphi Ventures, CSFB Private Equity, HBM BioVentures and Novo Ventures. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Ophthotech (Princeton, NJ) a clinical-stage biopharmaceutical company focused on ophthalmic therapies for wet and dry age-related macular degeneration, closed a $30M Series B financing. Participants include Clarus Ventures, SV Life Sciences, Novo Ventures and HBM BioVentures. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Probiodrug (Germany) a clinical-stage small molecule biopharmaceutical company focused upon Alzheimer’s and inflammation diseases, closed a $54M Series B financing. Participants include BB Biotech, Edmond de Rothschild Investment Partners, Life Science Partners, Biogen Idec New Ventures, HBM Bioventures and TVM Capital. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

MTM Laboratories (Germany) a commercial-stage molecular diagnostics company focused on cervical cancer, closed on an $10M bringing the Series C financing to $56M. Participants includeGilde Healthcare Partners , LBBW Venture Capital, HBM BioVentures, and HBM BioCapital. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Lux Biosciences (Jersey City, NJ) a clinical-stage biotechnology company focused on ophthalmic diseases, closed a $50M Series B financing. Participants include HBM Bioventures, De Novo Ventures, Prospect Venture Partners, SV Life Sciences and International Biotechnology Trust. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.